Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: Bill Tomko who wrote (371)	11/11/1997 4:04:00 PM
From: Ken Crooks	Respond to of 834

Some sales projections from presentation to American Heart Association at Orlando, excerpts from DJNews: "Butler said the cost of the drug is $200 a day per patient, and added that his sales estimates should be considered conservative. Butler estimates sales in 1998 at being $38 million for the HIT indication, which could grow to over $100 million by 2000. For acute myocardial infarction, the sales figures in 1999 are $22 million, which could grow to $45 million 2000. For stroke, the sales are not likely to begin until 2001. He believes those sales will be $100 million. Overall, potential peak sales for the drug are believed to be $38 million, moving to to roughly $150 million by 2000, and to $480 million in 2005." --------- Nothing earth-shaking in the rest of the article. Still looking at Spring 98 for approval of Novastan. While these numbers are nice, we still need success on the endothelin antagonist and/or asthma med testing to send this stock into orbit. '98 will be the show-and-tell year, IMO.